%0 Journal Article
%T Modulation of C1-Inhibitor and Plasma Kallikrein Activities by Type IV Collagen
%A Sriram Ravindran
%A Marc Schapira
%A Philip A. Patston
%J International Journal of Biomaterials
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/212417
%X The contact system of coagulation can be activated when in contact with biomaterials. As collagen is being tested in novel biomaterials in this study, we have investigated how type IV collagen affects plasma kallikrein and C1-inhibitor. Firstly, we showed C1-inhibitor binds to type IV collagen with a Kd of 0.86£¿¦ÌM. The effects of type IV collagen on plasma kallikrein, factor XIIa, and ¦Â-factor XIIa activity and on C1-inhibitor function were determined. Factor XIIa rapidly lost activity in the presence of type IV collagen, whereas plasma kallikrein and ¦Â-factor XIIa were more stable. The rate of inhibition of plasma kallikrein by C1-inhibitor was decreased by type IV collagen in a dose-dependent manner. These studies could be relevant to the properties of biomaterials, which contain collagen, and should be considered in the testing for biocompatibility. 1. Introduction Surface-dependent activation of factor XII and plasma prekallikrein is not believed to be a major component of the normal in vivo blood coagulation activation process [1]. However, contact activation readily occurs in vitro, as a result of contact with surfaces such as glass, kaolin, and other materials and during procedures such as cardiopulmonary bypass [2¨C5]. Under conditions such as these, factor XIIa could convert factor XI to factor XIa and result in unwanted thrombin generation. Therefore, it remains critical to understand the mechanisms of contact activation, as this has important implications for the thrombogenic properties and biocompatibility of many materials. For example, novel biomaterials are being developed for wound healing and drug delivery. Notably, many of these materials contain collagen [6¨C9]. Although collagens are naturally occurring molecules, if they are present in nonphysiological situations or at elevated concentrations, they might have unwanted properties, such as being thrombogenic [10]. C1-inhibitor is a proteinase inhibitor in the serpin family which is an important physiological inhibitor of plasma kallikrein and factor XIIa [11]. Previously we have shown that C1-inhibitor can bind to type IV collagen and that this can modulate the reaction with the complement proteinase C1s [12]. As C1-inhibitor is the main inhibitor of plasma kallikrein, we considered it to be important to investigate the effect of type IV collagen on the inhibition of plasma kallikrein by C1-inhibitor. In this study we have investigated binding of C1-inhibitor to type IV collagen in more detail and studied the effects of type IV collagen on plasma kallikrein and factor XIIa activities
%U http://www.hindawi.com/journals/ijbm/2012/212417/